Department of Perioperative Medicine, University Hospital of Clermont-Ferrand, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France; Université Clermont-Auvergne, CNRS, Inserm, GReD, 63000 Clermont-Ferrand, France.
Department of Perioperative Medicine, University Hospital of Clermont-Ferrand, 1, place Lucie-Aubrac, 63003 Clermont-Ferrand, France.
Anaesth Crit Care Pain Med. 2017 Oct;36(5):301-306. doi: 10.1016/j.accpm.2017.02.006. Epub 2017 Mar 18.
Different acute respiratory distress syndrome (ARDS) phenotypes may explain controversial results in clinical trials. Lung-morphology is one of the ARDS-phenotypes and physiological studies suggest different responses in terms of positive-end-expiratory-pressure (PEEP) and recruitment-manoeuvres (RM) according to loss of aeration. To evaluate whether tailored ventilator regimens may impact ARDS outcomes, our group has designed a randomised-clinical-trial of ventilator settings according to lung morphology in moderate-to-severe ARDS (LIVE study).
Patients will be enrolled within the first 12hours of ARDS onset. In both groups, volume-controlled ventilation with low tidal-volumes (Vt) will be used to target a plateau pressure≤30 cmHO. In the control group, the PEEP level and inspired fraction of oxygen (FiO) will be set using the ARDSNet table; a Vt of 6 mL/kg of predicted body weight (PBW) will be set and prone position (PP) will be applied. In the intervention arm, the ventilator will be set according to lung morphology (focal/non-focal) that will be assessed according to CT-scan±chest x-ray+lung echography. For focal ARDS patients, a Vt of 8 mL/kg PBW will be used along with low PEEP and PP. For non-focal ARDS patients, a Vt of 6 mL/kg PBW will be used with RM and PEEP to reach a plateau pressure≤30 cmHO. The primary outcome is all-cause 90-day mortality and the secondary outcomes are: in-hospital mortality, mortality at day 28, 60, 180 and 365; ventilator-free days at day 30, quality of life at one year; ventilator-associated pneumonia rate; barotrauma; ICU and hospital length of stay. This RCT is registered on Clinicaltrials.gov under identifier NCT02149589.
不同的急性呼吸窘迫综合征(ARDS)表型可能解释临床试验中存在争议的结果。肺形态学是 ARDS 表型之一,生理研究表明,根据通气丧失,在呼气末正压(PEEP)和复张手法(RM)方面存在不同的反应。为了评估针对肺形态学的呼吸机治疗方案是否会影响 ARDS 结局,我们小组设计了一项中度至重度 ARDS(LIVE 研究)根据肺形态学的呼吸机设置的随机临床试验。
患者将在 ARDS 发病后的 12 小时内入组。在两组中,将使用低潮气量(Vt)的容量控制通气来使平台压≤30cmH2O。在对照组中,将根据 ARDSNet 表设置 PEEP 水平和吸入氧分数(FiO2);设定 6mL/kg 预测体重(PBW)的 Vt,并应用俯卧位(PP)。在干预组中,将根据 CT 扫描±胸部 X 线+肺超声评估的肺形态(局灶性/非局灶性)来设置呼吸机。对于局灶性 ARDS 患者,将使用 8mL/kg PBW 的 Vt 并结合低 PEEP 和 PP。对于非局灶性 ARDS 患者,将使用 6mL/kg PBW 的 Vt 并进行 RM 和 PEEP 以达到平台压≤30cmH2O。主要结局是全因 90 天死亡率,次要结局是:住院死亡率、第 28 天、60 天、180 天和 365 天死亡率;第 30 天无呼吸机天数、1 年生活质量;呼吸机相关性肺炎发生率;气压伤;ICU 和住院时间。这项 RCT 在 ClinicalTrials.gov 上注册,标识符为 NCT02149589。